

Zhiwei Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2405528/publications.pdf>

Version: 2024-02-01

40
papers

1,883
citations

279798

23
h-index

377865

34
g-index

41
all docs

41
docs citations

41
times ranked

1966
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. <i>Blood</i> , 2007, 110, 133-141.	1.4	270
2	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. <i>Carcinogenesis</i> , 2015, 36, S254-S296.	2.8	239
3	Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , 2021, 75, 1271-1283.	3.7	162
4	Targeting tissue factor on tumor vascular endothelial cells and tumor cells for immunotherapy in mouse models of prostatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 12180-12185.	7.1	106
5	Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 8161-8166.	7.1	96
6	Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2679-2684.	7.1	86
7	Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer. <i>Scientific Reports</i> , 2020, 10, 2815.	3.3	73
8	The Immunoconjugate α CD133-Targeted Aberrantly Expressed Endothelial Tissue Factor Causing Regression of Endometriosis. <i>American Journal of Pathology</i> , 2010, 176, 1050-1056.	3.8	72
9	Platelet TLR4-ERK5 Axis Facilitates NET-Mediated Capturing of Circulating Tumor Cells and Distant Metastasis after Surgical Stress. <i>Cancer Research</i> , 2021, 81, 2373-2385.	0.9	72
10	Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 9221-9225.	7.1	67
11	Targeting tissue factor on tumour cells and angiogenic vascular endothelial cells by factor VII-targeted verteporfin photodynamic therapy for breast cancer in vitro and in vivo in mice. <i>BMC Cancer</i> , 2010, 10, 235.	2.6	56
12	Effective treatment of chemoresistant breast cancer in vitro and in vivo by a factor VII-targeted photodynamic therapy. <i>British Journal of Cancer</i> , 2011, 104, 1401-1409.	6.4	48
13	IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 489-502.	7.0	46
14	Targeting Tissue Factor for Immunotherapy of Choroidal Neovascularization by Intravitreal Delivery of Factor VII-Fc Chimeric Antibody. <i>Ocular Immunology and Inflammation</i> , 2007, 15, 3-10.	1.8	43
15	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. <i>Carcinogenesis</i> , 2015, 36, S184-S202.	2.8	41
16	Retroviral-mediated transmission of a mouse VL30 RNA to human melanoma cells promotes metastasis in an immunodeficient mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 6269-6273.	7.1	40
17	Mapping of angiogenic markers for targeting of vectors to tumor vascular endothelial cells. <i>Cancer Gene Therapy</i> , 2007, 14, 346-353.	4.6	37
18	Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy. <i>Angiogenesis</i> , 2017, 20, 85-96.	7.2	37

#	ARTICLE	IF	CITATIONS
19	Effective Treatment of Human Lung Cancer by Targeting Tissue Factor with a Factor VII-Targeted Photodynamic Therapy. <i>Current Cancer Drug Targets</i> , 2011, 11, 1069-1081.	1.6	33
20	Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. <i>Cancer Immunology Research</i> , 2018, 6, 671-684.	3.4	29
21	Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer. <i>Cancers</i> , 2021, 13, 5333.	3.7	29
22	Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. <i>BMC Immunology</i> , 2010, 11, 49.	2.2	26
23	hl-con1, a factor VII-IgGfc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. <i>British Journal of Cancer</i> , 2010, 103, 812-819.	6.4	26
24	Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 589-600.	2.5	26
25	Targeting tissue factor as a novel therapeutic oncotarget for eradication of cancer stem cells isolated from tumor cell lines, tumor xenografts and patients of breast, lung and ovarian cancer. <i>Oncotarget</i> , 2017, 8, 1481-1494.	1.8	26
26	Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer. <i>Molecules</i> , 2020, 25, 4964.	3.8	22
27	Factor VII-Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization. , 2009, 50, 3890.		18
28	Photodynamic Therapy as an Emerging Treatment Modality for Cancer and Non-Cancer Diseases. <i>Journal of Analytical & Bioanalytical Techniques</i> , 2014, S1, .	0.6	15
29	The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 4226-4229.	1.4	10
30	Therapeutic Antibody-Like Immunoconjugates against Tissue Factor with the Potential to Treat Angiogenesis-Dependent as Well as Macrophage-Associated Human Diseases. <i>Antibodies</i> , 2018, 7, 8.	2.5	8
31	Icon immunoconjugate treatment results in regression of red lesions in a non-human primate (Papio Tj ETQq1 1 0.784314 rgBT /Over 1.9		7
32	Overcome the Impairment of NK Cells for Icon and Antibody Immunotherapy of Cancer. <i>Journal of Immune Based Therapies, Vaccines and Antimicrobials</i> , 2013, 02, 1-8.	0.2	5
33	Factor VII-Targeted Photodynamic Therapy for Breast Cancer and Its Therapeutic Potential for Other Solid Cancers and Leukemia. , 0, , .		5
34	Fluorescent nanodiamonds and their use in biomedical research. , 2016, , .		3
35	Dual-Targeting of Tumor Cells and Tumor Neovasculature by Tissue Factor- Targeted Photodynamic Therapy. <i>Journal of Analytical & Bioanalytical Techniques</i> , 2012, 03, .	0.6	1
36	Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy. , 2021, , 193-212.		1

#	ARTICLE	IF	CITATIONS
37	Tumor Cell-Associated Tissue Factor Supports Metastatic Potential through Both NK Cell-Dependent and -Independent Mechanisms.. Blood, 2006, 108, 66-66.	1.4	1
38	Interplay between Tumor Cell-Associated and Circulating Coagulation Factors in Establishing Metastatic Potential.. Blood, 2005, 106, 686-686.	1.4	1
39	Antigen-Driven Stimulation of B-Lymphocytes In Vitro. , 2002, 178, 113-119.		0
40	Tissue factor-targeted immunotherapy of melanoma and triple negative breast cancer using a second generation ICON. , 2015, 3, .		0